broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K72951360-001-01-4 | ACH-000217 | JHH6_LIVER | HTS002 | 1 | 0.046976 | 1.515511 | 0.609016 | 0.683949 | 0.402298 | 0.429359 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000217 |
BRD-K72951360-001-01-4 | ACH-000463 | NCIH460_LUNG | HTS002 | 1 | 0.063381 | 2.159825 | 0.867688 | 0.582818 | 0.132696 | 0.14129 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000463 |
BRD-K72951360-001-01-4 | ACH-000748 | SJSA1_BONE | HTS002 | 1 | 0.000167 | 4.361378 | 0.323281 | 0.880728 | 3.146973 | 3.147214 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000748 |
BRD-K72951360-001-01-4 | ACH-000788 | A2058_SKIN | HTS002 | 1 | 0.040456 | 6.092138 | 0.846533 | 0.582057 | 0.145998 | 0.148034 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000788 |
BRD-K72951360-001-01-4 | ACH-000545 | VMCUB1_URINARY_TRACT | HTS002 | 1 | 0.021276 | 1.237632 | 0.426773 | 0.723015 | 0.659401 | 0.68298 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000545 |
BRD-K72951360-001-01-4 | ACH-000762 | YD38_UPPER_AERODIGESTIVE_TRACT | HTS002 | 1 | -0.000074 | 3.286509 | 0.478259 | 0.643022 | 0.312998 | 0.312984 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000762 |
BRD-K72951360-001-01-4 | ACH-000792 | BFTC909_KIDNEY | HTS002 | 1 | 0.006875 | 13.320607 | 0.23389 | 0.773596 | 1.09454 | 1.095679 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000792 |
BRD-K72951360-001-01-4 | ACH-000211 | DAOY_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | 0.001896 | 3.996788 | 0.709558 | 0.554757 | 0.131823 | 0.131948 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000211 |
BRD-K72951360-001-01-4 | ACH-000936 | EFO27_OVARY | HTS002 | 1 | 0.057973 | 6.702278 | 0.640031 | 0.709054 | 0.49931 | 0.508576 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000936 |
BRD-K72951360-001-01-4 | ACH-000882 | IGR1_SKIN | HTS002 | 1 | 0.005765 | 1.521846 | 0.75393 | 0.712854 | 0.612151 | 0.616833 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000882 |
BRD-K72951360-001-01-4 | ACH-000471 | LI7_LIVER | HTS002 | 1 | 0.006717 | 7.387095 | 0.683157 | 0.697492 | 0.520573 | 0.521527 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000471 |
BRD-K72951360-001-01-4 | ACH-000670 | SBC5_LUNG | HTS002 | 1 | 0.062729 | 5.166902 | 0.905936 | 0.590438 | 0.144016 | 0.147801 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000670 |
BRD-K72951360-001-01-4 | ACH-000048 | TOV112D_OVARY | HTS002 | 1 | 0.019313 | 9.194728 | 0.522011 | 0.682656 | 0.43275 | 0.434608 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000048 |
BRD-K72951360-001-01-4 | ACH-000259 | KELLY_AUTONOMIC_GANGLIA | HTS002 | 1 | 0.043494 | 6.00054 | 0.802583 | 0.703845 | 0.49559 | 0.503164 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000259 |
BRD-K72951360-001-01-4 | ACH-000599 | PATU8902_PANCREAS | HTS002 | 1 | 0.029488 | 1.258897 | 0.727813 | 0.600395 | 0.184809 | 0.193952 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000599 |
BRD-K72951360-001-01-4 | ACH-000716 | TT2609C02_THYROID | HTS002 | 1 | 0.019181 | 5.51549 | 0.598346 | 0.683554 | 0.436798 | 0.439907 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000716 |
BRD-K72951360-001-01-4 | ACH-000347 | QGP1_PANCREAS | HTS002 | 1 | 0.052597 | 22.545351 | 0.467523 | 0.819964 | 1.581718 | 1.589535 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000347 |
BRD-K72951360-001-01-4 | ACH-000566 | SW1710_URINARY_TRACT | HTS002 | 1 | 0.042073 | 7.887352 | 0.827988 | 0.579034 | 0.140588 | 0.142163 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000566 |
BRD-K72951360-001-01-4 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | 0.034006 | 1.224501 | 0.780187 | 0.635937 | 0.260316 | 0.275729 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-001016 |
BRD-K72951360-001-01-4 | ACH-000395 | NCIH520_LUNG | HTS002 | 1 | 0.05375 | 1.583592 | 0.400198 | 0.741399 | 0.711831 | 0.764833 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000395 |
BRD-K72951360-001-01-4 | ACH-000407 | SNU685_ENDOMETRIUM | HTS002 | 1 | 0.033057 | 4.573379 | 0.481857 | 0.684232 | 0.420457 | 0.426792 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000407 |
BRD-K72951360-001-01-4 | ACH-000418 | SW1353_BONE | HTS002 | 1 | -0.10787 | 0.776276 | 0.222779 | 0.713228 | 0.720029 | 0.559832 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000418 |
BRD-K72951360-001-01-4 | ACH-000008 | A101D_SKIN | HTS002 | 1 | 0.000366 | 1.48637 | 0.793557 | 0.638068 | 0.298989 | 0.299136 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000008 |
BRD-K72951360-001-01-4 | ACH-000191 | BHT101_THYROID | HTS002 | 1 | 0.009315 | 1.304799 | 0.587475 | 0.595821 | 0.191567 | 0.194348 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000191 |
BRD-K72951360-001-01-4 | ACH-000941 | HEC1B_ENDOMETRIUM | HTS002 | 1 | 0.000308 | 0.883245 | 0.660832 | 0.800637 | 1.808005 | 1.809265 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000941 |
BRD-K72951360-001-01-4 | ACH-000532 | SNU61_LARGE_INTESTINE | HTS002 | 1 | 0.012715 | 2.708738 | 0.724585 | 0.643088 | 0.299542 | 0.302405 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000532 |
BRD-K72951360-001-01-4 | ACH-000316 | SNU886_LIVER | HTS002 | 1 | 0.020556 | 3.696865 | 0.7325 | 0.576343 | 0.150333 | 0.15205 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000316 |
BRD-K72951360-001-01-4 | ACH-000677 | SW1573_LUNG | HTS002 | 1 | 0.000501 | 1.098112 | 0.78499 | 0.582986 | 0.176 | 0.176161 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000677 |
BRD-K72951360-001-01-4 | ACH-000375 | G402_SOFT_TISSUE | HTS002 | 1 | 0.004666 | 1.350819 | 0.788718 | 0.46939 | 0.056609 | 0.057003 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000375 |
BRD-K72951360-001-01-4 | ACH-000619 | PECAPJ15_UPPER_AERODIGESTIVE_TRACT | HTS002 | 1 | 0.037887 | 11.485273 | 0.674235 | 0.585777 | 0.1533 | 0.154355 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000619 |
BRD-K72951360-001-01-4 | ACH-000965 | RL952_ENDOMETRIUM | HTS002 | 1 | 0.035268 | 1.75361 | 0.661475 | 0.553218 | 0.111763 | 0.116524 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000965 |
BRD-K72951360-001-01-4 | ACH-000210 | CADOES1_BONE | HTS002 | 1 | 0.017655 | 16.630178 | 0.282553 | 0.909139 | 4.075603 | 4.084422 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000210 |
BRD-K72951360-001-01-4 | ACH-000803 | COLO668_LUNG | HTS002 | 1 | 0.023947 | 5.866264 | 0.210648 | 0.677961 | 0.406903 | 0.410321 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000803 |
BRD-K72951360-001-01-4 | ACH-000007 | LS513_LARGE_INTESTINE | HTS002 | 1 | -0.004452 | 1.155511 | 0.358937 | 0.650495 | 0.34223 | 0.339614 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000007 |
BRD-K72951360-001-01-4 | ACH-000719 | RMGI_OVARY | HTS002 | 1 | 0.001776 | 9.562309 | 0.686022 | 0.706593 | 0.577109 | 0.577324 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000719 |
BRD-K72951360-001-01-4 | ACH-000484 | VMRCRCW_KIDNEY | HTS002 | 1 | 0.091023 | 2.552803 | 0.553857 | 0.72554 | 0.534045 | 0.577782 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000484 |
BRD-K72951360-001-01-4 | ACH-000433 | CAKI1_KIDNEY | HTS002 | 1 | 0.028789 | 3.093996 | 0.429068 | 0.701234 | 0.505314 | 0.515092 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000433 |
BRD-K72951360-001-01-4 | ACH-000688 | OV7_OVARY | HTS002 | 1 | 0.038974 | 12.410009 | 0.360113 | 0.850597 | 2.21216 | 2.226674 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000688 |
BRD-K72951360-001-01-4 | ACH-000603 | BEN_LUNG | HTS002 | 1 | -0.082965 | 0.963549 | 0.669076 | 0.79692 | 1.648093 | 1.405358 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000603 |
BRD-K72951360-001-01-4 | ACH-000351 | MKN1_STOMACH | HTS002 | 1 | 0.007566 | 1.777806 | 0.879945 | 0.486217 | 0.065791 | 0.066357 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000351 |
BRD-K72951360-001-01-4 | ACH-000627 | LCLC103H_LUNG | HTS002 | 1 | 0.00928 | 1.904093 | 0.791833 | 0.614145 | 0.228444 | 0.230703 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000627 |
BRD-K72951360-001-01-4 | ACH-000916 | NCIH1573_LUNG | HTS002 | 1 | 0.052672 | 1.175617 | 0.483278 | 0.642108 | 0.258534 | 0.28421 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000916 |
BRD-K72951360-001-01-4 | ACH-000863 | DBTRG05MG_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | -0.000167 | 6.459754 | 0.675051 | 0.691449 | 0.500764 | 0.500738 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000863 |
BRD-K72951360-001-01-4 | ACH-000732 | PECAPJ41CLONED2_UPPER_AERODIGESTIVE_TRACT | HTS002 | 1 | 0.011182 | 20.848701 | 0.814834 | 0.572969 | 0.151341 | 0.151506 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000732 |
BRD-K72951360-001-01-4 | ACH-000066 | HCC4006_LUNG | HTS002 | 1 | 0.000095 | 1.189399 | 0.66148 | 0.7237 | 0.709116 | 0.709229 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000066 |
BRD-K72951360-001-01-4 | ACH-000015 | NCIH1581_LUNG | HTS002 | 1 | 0.011946 | 2.224976 | 0.449567 | 0.689667 | 0.474826 | 0.480015 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000015 |
BRD-K72951360-001-01-4 | null | null | HTS002 | 1 | 0.009449 | 1.642012 | 0.681388 | 0.628583 | 0.26328 | 0.266357 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | false | ACH-000511_FAILED_STR |
BRD-K72951360-001-01-4 | ACH-000674 | NUGC4_STOMACH | HTS002 | 1 | 0.013768 | 1.860164 | 0.844056 | 0.540942 | 0.109235 | 0.110887 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000674 |
BRD-K72951360-001-01-4 | ACH-000892 | NCIH1563_LUNG | HTS002 | 1 | -0.004558 | 0.93533 | 0.871107 | 0.626698 | 0.276134 | 0.273467 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000892 |
BRD-K72951360-001-01-4 | ACH-000909 | JHUEM2_ENDOMETRIUM | HTS002 | 1 | 0.005907 | 1.501474 | 0.972946 | 0.442714 | 0.043352 | 0.043696 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000909 |
BRD-K72951360-001-01-4 | ACH-000237 | JHOM1_OVARY | HTS002 | 1 | 0.018726 | 7.714124 | 0.721911 | 0.684936 | 0.443452 | 0.445652 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000237 |
BRD-K72951360-001-01-4 | ACH-000811 | SKOV3_OVARY | HTS002 | 1 | 0.021002 | 3.034191 | 0.589658 | 0.671535 | 0.385493 | 0.390984 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000811 |
BRD-K72951360-001-01-4 | ACH-000312 | SKNBE2_AUTONOMIC_GANGLIA | HTS002 | 1 | 0.004768 | 1.586118 | 0.604392 | 0.652158 | 0.337502 | 0.339547 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000312 |
BRD-K72951360-001-01-4 | ACH-000390 | LUDLU1_LUNG | HTS002 | 1 | 0.026034 | 1.202638 | 0.472243 | 0.718685 | 0.624113 | 0.652489 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000390 |
BRD-K72951360-001-01-4 | ACH-000901 | HCC1359_LUNG | HTS002 | 1 | 0.005588 | 1.682321 | 0.435003 | 0.631625 | 0.275036 | 0.27688 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000901 |
BRD-K72951360-001-01-4 | ACH-000307 | PK1_PANCREAS | HTS002 | 1 | 0.004604 | 1.526795 | 0.579138 | 0.632202 | 0.277935 | 0.279624 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000307 |
BRD-K72951360-001-01-4 | ACH-000289 | SNU466_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | -0.133374 | 0.698056 | 0.601143 | 0.700586 | 0.661419 | 0.471376 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000289 |
BRD-K72951360-001-01-4 | ACH-000309 | SKLU1_LUNG | HTS002 | 1 | 0.017286 | 6.920964 | 0.485297 | 0.687968 | 0.459019 | 0.461359 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000309 |
BRD-K72951360-001-01-4 | ACH-000733 | NCIH1838_LUNG | HTS002 | 1 | 0.018115 | 4.835398 | 0.527797 | 0.577536 | 0.153711 | 0.154889 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000733 |
BRD-K72951360-001-01-4 | ACH-000268 | SNU245_BILIARY_TRACT | HTS002 | 1 | 0.171243 | 6.593828 | 0.339494 | 0.76428 | 0.632858 | 0.674407 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000268 |
BRD-K72951360-001-01-4 | ACH-000758 | MKN74_STOMACH | HTS002 | 1 | 0.058141 | 3.320474 | 0.300013 | 0.855213 | 2.254566 | 2.340084 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000758 |
BRD-K72951360-001-01-4 | ACH-000693 | KYSE180_OESOPHAGUS | HTS002 | 1 | 0.047727 | 4.170814 | 0.856808 | 0.697675 | 0.459214 | 0.470393 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000693 |
BRD-K72951360-001-01-4 | ACH-000684 | KMRC1_KIDNEY | HTS002 | 1 | 0.072167 | 1.512641 | 0.333475 | 0.608492 | 0.166805 | 0.18491 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000684 |
BRD-K72951360-001-01-4 | ACH-000264 | CALU6_LUNG | HTS002 | 1 | 0.129862 | 11.062357 | 0.809234 | 0.624458 | 0.151739 | 0.155921 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000264 |
BRD-K72951360-001-01-4 | ACH-000027 | GOS3_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | -0.053066 | 1.118628 | 0.634793 | 0.748471 | 0.924717 | 0.844982 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000027 |
BRD-K72951360-001-01-4 | ACH-000671 | HUH6_LIVER | HTS002 | 1 | 0.042645 | 7.365177 | 0.632018 | 0.598262 | 0.170406 | 0.172481 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000671 |
BRD-K72951360-001-01-4 | ACH-000205 | PK59_PANCREAS | HTS002 | 1 | 0.028413 | 1.712142 | 0.716764 | 0.573884 | 0.14184 | 0.14677 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000205 |
BRD-K72951360-001-01-4 | ACH-000720 | TCCSUP_URINARY_TRACT | HTS002 | 1 | 0.055462 | 8.98435 | 0.509636 | 0.712664 | 0.522322 | 0.529202 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000720 |
BRD-K72951360-001-01-4 | ACH-000814 | HS939T_SKIN | HTS002 | 1 | 0.00014 | 11.083271 | 0.5998 | 0.700357 | 0.545757 | 0.545771 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000814 |
BRD-K72951360-001-01-4 | ACH-000885 | TOV21G_OVARY | HTS002 | 1 | 0.008438 | 1.404687 | 0.807313 | 0.429879 | 0.03767 | 0.038129 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000885 |
BRD-K72951360-001-01-4 | ACH-000663 | OVTOKO_OVARY | HTS002 | 1 | 0.111766 | 4.811852 | 0.469645 | 0.736085 | 0.559492 | 0.589696 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000663 |
BRD-K72951360-001-01-4 | ACH-000647 | TE1_OESOPHAGUS | HTS002 | 1 | 0.002597 | 1.789963 | 0.618302 | 0.644014 | 0.31355 | 0.314463 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000647 |
BRD-K72951360-001-01-4 | ACH-000243 | DANG_PANCREAS | HTS002 | 1 | 0.013551 | 2.157034 | 0.55308 | 0.602428 | 0.200211 | 0.202778 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000243 |
BRD-K72951360-001-01-4 | ACH-000255 | LMSU_STOMACH | HTS002 | 1 | 0.000345 | 1.500957 | 0.618506 | 0.567833 | 0.150832 | 0.150901 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000255 |
BRD-K72951360-001-01-4 | ACH-000335 | MSTO211H_PLEURA | HTS002 | 1 | -0.0001 | 1.11445 | 0.706476 | 0.516481 | 0.091806 | 0.09179 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000335 |
BRD-K72951360-001-01-4 | ACH-000147 | T47D_BREAST | HTS002 | 1 | 0.026436 | 1.412009 | 0.579044 | 0.567006 | 0.133712 | 0.138956 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000147 |
BRD-K72951360-001-01-4 | ACH-000090 | PC3_PROSTATE | HTS002 | 1 | 0.127461 | 2.783892 | 0.759419 | 0.634286 | 0.171228 | 0.190318 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000090 |
BRD-K72951360-001-01-4 | ACH-000171 | VMRCRCZ_KIDNEY | HTS002 | 1 | 0.033955 | 5.433957 | 0.502877 | 0.699 | 0.486262 | 0.492596 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000171 |
BRD-K72951360-001-01-4 | ACH-000614 | RVH421_SKIN | HTS002 | 1 | 0.002889 | 1.306429 | 0.685826 | 0.612496 | 0.231439 | 0.232468 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000614 |
BRD-K72951360-001-01-4 | ACH-000132 | JHOS2_OVARY | HTS002 | 1 | 0.139144 | 7.716213 | 0.534213 | 0.648729 | 0.190682 | 0.198914 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000132 |
BRD-K72951360-001-01-4 | ACH-000274 | HS852T_SKIN | HTS002 | 1 | -0.031499 | 2.660107 | 0.676001 | 0.888525 | 3.464595 | 3.385933 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000274 |
BRD-K72951360-001-01-4 | null | null | HTS002 | 1 | 0.000837 | 1.525819 | 0.768861 | 0.658275 | 0.363418 | 0.363817 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | false | ACH-000807_FAILED_STR |
BRD-K72951360-001-01-4 | ACH-000810 | SKMEL30_SKIN | HTS002 | 1 | 0.004688 | 1.650798 | 0.563861 | 0.713819 | 0.617829 | 0.621365 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000810 |
BRD-K72951360-001-01-4 | ACH-000343 | NCIH522_LUNG | HTS002 | 1 | 0.095803 | 7.68532 | 0.410104 | 0.724083 | 0.51756 | 0.532084 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000343 |
BRD-K72951360-001-01-4 | ACH-000022 | PATU8988S_PANCREAS | HTS002 | 1 | 0.436604 | 13.146116 | 0.274374 | 0.865521 | 0.986377 | 1.154168 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000022 |
BRD-K72951360-001-01-4 | ACH-000192 | MFE280_ENDOMETRIUM | HTS002 | 1 | 0.005181 | 1.685207 | 0.647637 | 0.49759 | 0.074403 | 0.074864 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000192 |
BRD-K72951360-001-01-4 | null | null | HTS002 | 1 | 0.205677 | 1.912581 | 0.607508 | 0.694702 | 0.240084 | 0.316735 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | false | ACH-000409_FAILED_STR |
BRD-K72951360-001-01-4 | ACH-000959 | SNUC4_LARGE_INTESTINE | HTS002 | 1 | 0.105223 | 2.210771 | 0.824859 | 0.658465 | 0.24627 | 0.27405 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000959 |
BRD-K72951360-001-01-4 | null | null | HTS002 | 1 | 0.012142 | 2.049047 | 0.801491 | 0.65539 | 0.33886 | 0.34295 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | false | ACH-000028_FAILED_STR |
BRD-K72951360-001-01-4 | ACH-000637 | KYSE520_OESOPHAGUS | HTS002 | 1 | -0.02858 | 0.907459 | 0.766682 | 0.645325 | 0.335088 | 0.315178 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000637 |
BRD-K72951360-001-01-4 | ACH-000968 | COLO792_SKIN | HTS002 | 1 | 0.006345 | 14.866391 | 0.488708 | 0.790379 | 1.290995 | 1.292105 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000968 |
BRD-K72951360-001-01-4 | ACH-000155 | SW1990_PANCREAS | HTS002 | 1 | 0.066093 | 1.674886 | 0.784983 | 0.630623 | 0.215538 | 0.234578 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000155 |
BRD-K72951360-001-01-4 | ACH-000133 | HS729_SOFT_TISSUE | HTS002 | 1 | 0.008802 | 3.884325 | 0.367492 | 0.664597 | 0.3749 | 0.376619 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000133 |
BRD-K72951360-001-01-4 | ACH-000605 | TE6_OESOPHAGUS | HTS002 | 1 | 0.074362 | 1.98571 | 0.684519 | 0.598914 | 0.149247 | 0.161853 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000605 |
BRD-K72951360-001-01-4 | ACH-000775 | NCIH727_LUNG | HTS002 | 1 | 0.120583 | 1.584194 | 0.082699 | 0.883383 | 3.015649 | 3.58952 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000775 |
BRD-K72951360-001-01-4 | ACH-000042 | PANC0203_PANCREAS | HTS002 | 1 | 0.054245 | 4.195355 | 0.793598 | 0.688656 | 0.40983 | 0.421203 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000042 |
BRD-K72951360-001-01-4 | ACH-000860 | NCIH358_LUNG | HTS002 | 1 | 0.005277 | 1.350081 | 0.642883 | 0.618255 | 0.242462 | 0.244375 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000860 |
BRD-K72951360-001-01-4 | ACH-000994 | HEC59_ENDOMETRIUM | HTS002 | 1 | -0.003214 | 1.429226 | 0.849271 | 0.657423 | 0.362108 | 0.360488 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000994 |
BRD-K72951360-001-01-4 | ACH-000277 | HCC1419_BREAST | HTS002 | 1 | -0.121042 | 0.848794 | 0.520795 | 0.754034 | 1.083226 | 0.839065 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000277 |
BRD-K72951360-001-01-4 | ACH-000496 | NCIH1792_LUNG | HTS002 | 1 | 0.034463 | 9.20614 | 0.495707 | 0.586098 | 0.156092 | 0.157307 | valrubicin | DNA inhibitor, topoisomerase inhibitor | TOP2A | oncology | bladder cancer | CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1 | Launched | true | ACH-000496 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.